The U.S. is expected to account for around one-third of the total share in the global benzodiazepine drugs market by 2026. Growing prevalence of anxiety in parallel with rising awareness regarding benzodiazepine drugs is reflecting on increasing opportunities for players in the U.S. market. As per
More
